NZ716568A - Inhibitors of the farnesoid x receptor and uses in medicine - Google Patents

Info

Publication number

NZ716568A

NZ716568A NZ716568A NZ71656814A NZ716568A NZ 716568 A NZ716568 A NZ 716568A NZ 716568 A NZ716568 A NZ 716568A NZ 71656814 A NZ71656814 A NZ 71656814A NZ 716568 A NZ716568 A NZ 716568A

Authority

NZ

New Zealand

Prior art keywords

mice

mca

weeks

gly

treated

Prior art date

2013-08-01

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 title claims description 10
• 102100038495 Bile acid receptor Human genes 0.000 title abstract description 12
• 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title abstract description 12
• 239000003112 inhibitor Substances 0.000 title abstract description 5
• 150000001875 compounds Chemical class 0.000 claims abstract description 98
• 208000008589 Obesity Diseases 0.000 claims abstract description 52
• 235000020824 obesity Nutrition 0.000 claims abstract description 52
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 51
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 25
• 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 21
• 150000003839 salts Chemical class 0.000 claims description 29
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
• 201000010099 disease Diseases 0.000 claims description 11
• 208000035475 disorder Diseases 0.000 claims description 10
• 238000002360 preparation method Methods 0.000 claims description 4
• 208000010706 fatty liver disease Diseases 0.000 claims 1
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 40
• 241000124008 Mammalia Species 0.000 abstract description 38
• 238000000034 method Methods 0.000 abstract description 33
• 230000002401 inhibitory effect Effects 0.000 abstract description 3
• 241000699670 Mus sp. Species 0.000 description 320
• 235000009200 high fat diet Nutrition 0.000 description 160
• 210000004185 liver Anatomy 0.000 description 114
• 238000011282 treatment Methods 0.000 description 84
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 75
• 210000003405 ileum Anatomy 0.000 description 61
• 239000003981 vehicle Substances 0.000 description 60
• 108020004999 messenger RNA Proteins 0.000 description 58
• 230000003115 biocidal effect Effects 0.000 description 50
• 150000002500 ions Chemical class 0.000 description 48
• 108090000623 proteins and genes Proteins 0.000 description 48
• 239000003613 bile acid Substances 0.000 description 42
• XSOLDPYUICCHJX-UZUDEGBHSA-N tauro-beta-muricholic acid Chemical compound C([C@H]1[C@H](O)[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 XSOLDPYUICCHJX-UZUDEGBHSA-N 0.000 description 42
• 210000004027 cell Anatomy 0.000 description 39
• 229940106189 ceramide Drugs 0.000 description 35
• 101150027485 NR1H4 gene Proteins 0.000 description 34
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 33
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 32
• 238000004458 analytical method Methods 0.000 description 31
• 230000000694 effects Effects 0.000 description 31
• 229910052739 hydrogen Inorganic materials 0.000 description 31
• 239000001257 hydrogen Substances 0.000 description 30
• 210000002966 serum Anatomy 0.000 description 30
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
• 230000003247 decreasing effect Effects 0.000 description 28
• WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 25
• WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 25
• 150000002431 hydrogen Chemical group 0.000 description 24
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 23
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 23
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 23
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 23
• 235000005911 diet Nutrition 0.000 description 23
• 210000003608 fece Anatomy 0.000 description 23
• 150000002632 lipids Chemical class 0.000 description 23
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 23
• 230000037213 diet Effects 0.000 description 22
• 101150004229 NR0B2 gene Proteins 0.000 description 21
• 101150096065 shp gene Proteins 0.000 description 21
• 230000037396 body weight Effects 0.000 description 20
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
• 230000000968 intestinal effect Effects 0.000 description 19
• 210000000936 intestine Anatomy 0.000 description 19
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
• 230000002440 hepatic effect Effects 0.000 description 17
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
• 241000699666 Mus <mouse, genus> Species 0.000 description 16
• 229960003080 taurine Drugs 0.000 description 16
• 108010000231 Choloylglycine hydrolase Proteins 0.000 description 15
• 229960001091 chenodeoxycholic acid Drugs 0.000 description 15
• 230000005764 inhibitory process Effects 0.000 description 15
• 230000002829 reductive effect Effects 0.000 description 15
• RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 14
• 238000005481 NMR spectroscopy Methods 0.000 description 14
• 239000002253 acid Substances 0.000 description 14
• 125000000217 alkyl group Chemical group 0.000 description 14
• RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 14
• -1 fatty acid ion Chemical class 0.000 description 14
• 244000005709 gut microbiome Species 0.000 description 14
• 238000011068 loading method Methods 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 102000005962 receptors Human genes 0.000 description 14
• 108020003175 receptors Proteins 0.000 description 14
• 229910001868 water Inorganic materials 0.000 description 14
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
• 235000014113 dietary fatty acids Nutrition 0.000 description 13
• 229930195729 fatty acid Natural products 0.000 description 13
• 239000000194 fatty acid Substances 0.000 description 13
• 230000002550 fecal effect Effects 0.000 description 13
• 239000008103 glucose Substances 0.000 description 13
• 210000003494 hepatocyte Anatomy 0.000 description 13
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
• DKPMWHFRUGMUKF-CRKPLTDNSA-N beta-muricholic acid Chemical compound C([C@H]1[C@H](O)[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DKPMWHFRUGMUKF-CRKPLTDNSA-N 0.000 description 12
• 150000001783 ceramides Chemical class 0.000 description 12
• 150000004665 fatty acids Chemical class 0.000 description 12
• 239000002502 liposome Substances 0.000 description 12
• 210000004877 mucosa Anatomy 0.000 description 12
• 235000019786 weight gain Nutrition 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 11
• 239000000284 extract Substances 0.000 description 11
• 239000006187 pill Substances 0.000 description 11
• 210000002700 urine Anatomy 0.000 description 11
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 10
• 108010082126 Alanine transaminase Proteins 0.000 description 10
• 238000011814 C57BL/6N mouse Methods 0.000 description 10
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
• 239000004471 Glycine Substances 0.000 description 10
• 102000004877 Insulin Human genes 0.000 description 10
• 108090001061 Insulin Proteins 0.000 description 10
• 101100390675 Mus musculus Fgf15 gene Proteins 0.000 description 10
• 229940125396 insulin Drugs 0.000 description 10
• 238000003786 synthesis reaction Methods 0.000 description 10
• 210000001519 tissue Anatomy 0.000 description 10
• 239000005089 Luciferase Substances 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• 239000003858 bile acid conjugate Substances 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 9
• 238000011534 incubation Methods 0.000 description 9
• 230000004060 metabolic process Effects 0.000 description 9
• 238000002705 metabolomic analysis Methods 0.000 description 9
• 230000001431 metabolomic effect Effects 0.000 description 9
• 230000011664 signaling Effects 0.000 description 9
• 230000004584 weight gain Effects 0.000 description 9
• 238000001262 western blot Methods 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 8
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 108060001084 Luciferase Proteins 0.000 description 7
• 229910006069 SO3H Inorganic materials 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
• 230000002438 mitochondrial effect Effects 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
• 102100032141 Cell death activator CIDE-A Human genes 0.000 description 6
• 108090000331 Firefly luciferases Proteins 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000775570 Homo sapiens Cell death activator CIDE-A Proteins 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• 125000003118 aryl group Chemical group 0.000 description 6
• 125000004432 carbon atom Chemical group C* 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 210000001035 gastrointestinal tract Anatomy 0.000 description 6
• 238000007446 glucose tolerance test Methods 0.000 description 6
• 125000005843 halogen group Chemical group 0.000 description 6
• 230000014759 maintenance of location Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 239000002207 metabolite Substances 0.000 description 6
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 229910052717 sulfur Inorganic materials 0.000 description 6
• 239000003643 water by type Substances 0.000 description 6
• 208000024172 Cardiovascular disease Diseases 0.000 description 5
• 108020004414 DNA Proteins 0.000 description 5
• 241000192125 Firmicutes Species 0.000 description 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
• 238000011529 RT qPCR Methods 0.000 description 5
• 229930006000 Sucrose Natural products 0.000 description 5
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 235000013361 beverage Nutrition 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 238000006243 chemical reaction Methods 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 230000037406 food intake Effects 0.000 description 5
• 235000012631 food intake Nutrition 0.000 description 5
• VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 102000006255 nuclear receptors Human genes 0.000 description 5
• 108020004017 nuclear receptors Proteins 0.000 description 5
• 125000003729 nucleotide group Chemical group 0.000 description 5
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
• 238000007254 oxidation reaction Methods 0.000 description 5
• JPAUCQAJHLSMQW-XPORZQOISA-N p-tolyl beta-D-glucuronide Chemical compound C1=CC(C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 JPAUCQAJHLSMQW-XPORZQOISA-N 0.000 description 5
• 238000012163 sequencing technique Methods 0.000 description 5
• 210000000813 small intestine Anatomy 0.000 description 5
• 230000003595 spectral effect Effects 0.000 description 5
• 239000005720 sucrose Substances 0.000 description 5
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
• ZEMLYWMOSZRCQL-UWSZBUKDSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-[(2s)-1-[(2-methylpropan-2-yl)oxy]-1-oxobutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@H](CC(O)=O)C2)=O)[C@@H](CC)C(=O)OC(C)(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 ZEMLYWMOSZRCQL-UWSZBUKDSA-N 0.000 description 4
• 108010001478 Bacitracin Proteins 0.000 description 4
• 241000605059 Bacteroidetes Species 0.000 description 4
• 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 4
• 101710176143 Cytochrome P450 7A1 Proteins 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• 102100039556 Galectin-4 Human genes 0.000 description 4
• 206010019708 Hepatic steatosis Diseases 0.000 description 4
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 4
• 241000186660 Lactobacillus Species 0.000 description 4
• 229930193140 Neomycin Natural products 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
• NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 108090000340 Transaminases Proteins 0.000 description 4
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 229940024606 amino acid Drugs 0.000 description 4
• 235000001014 amino acid Nutrition 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 4
• 229960003071 bacitracin Drugs 0.000 description 4
• 229930184125 bacitracin Natural products 0.000 description 4
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 4
• 239000000090 biomarker Substances 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 235000012000 cholesterol Nutrition 0.000 description 4
• 230000001186 cumulative effect Effects 0.000 description 4
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
• UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
• 230000004136 fatty acid synthesis Effects 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 231100000304 hepatotoxicity Toxicity 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 229940039696 lactobacillus Drugs 0.000 description 4
• 208000019423 liver disease Diseases 0.000 description 4
• 230000007056 liver toxicity Effects 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 210000003470 mitochondria Anatomy 0.000 description 4
• 229960004927 neomycin Drugs 0.000 description 4
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
• 239000002773 nucleotide Substances 0.000 description 4
• 238000013116 obese mouse model Methods 0.000 description 4
• 229920001542 oligosaccharide Polymers 0.000 description 4
• 150000002482 oligosaccharides Chemical class 0.000 description 4
• 230000003647 oxidation Effects 0.000 description 4
• 238000010239 partial least squares discriminant analysis Methods 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 230000029058 respiratory gaseous exchange Effects 0.000 description 4
• 235000021391 short chain fatty acids Nutrition 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000012453 solvate Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 229960005322 streptomycin Drugs 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 238000004885 tandem mass spectrometry Methods 0.000 description 4
• QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 4
• 102000014898 transaminase activity proteins Human genes 0.000 description 4
• 230000004580 weight loss Effects 0.000 description 4
• 108020004465 16S ribosomal RNA Proteins 0.000 description 3
• 238000005160 1H NMR spectroscopy Methods 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 101150075266 CYP7A1 gene Proteins 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 229920002527 Glycogen Polymers 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 101100220687 Mus musculus Cidea gene Proteins 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 108010026552 Proteome Proteins 0.000 description 3
• 241000242739 Renilla Species 0.000 description 3
• 108091027981 Response element Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 210000000577 adipose tissue Anatomy 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 229940088710 antibiotic agent Drugs 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 235000019577 caloric intake Nutrition 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 210000004534 cecum Anatomy 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 108700010039 chimeric receptor Proteins 0.000 description 3
• 230000007882 cirrhosis Effects 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000001514 detection method Methods 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 238000013229 diet-induced obese mouse Methods 0.000 description 3
• 235000021045 dietary change Nutrition 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 230000032050 esterification Effects 0.000 description 3
• 238000005886 esterification reaction Methods 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 235000021588 free fatty acids Nutrition 0.000 description 3
• 229940096919 glycogen Drugs 0.000 description 3
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
• 239000000833 heterodimer Substances 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 150000002576 ketones Chemical class 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 230000037356 lipid metabolism Effects 0.000 description 3
• 235000004213 low-fat Nutrition 0.000 description 3
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 238000000491 multivariate analysis Methods 0.000 description 3
• 230000010627 oxidative phosphorylation Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 231100000272 reduced body weight Toxicity 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
• 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• 235000016804 zinc Nutrition 0.000 description 3
• QQVDJLLNRSOCEL-UHFFFAOYSA-N (2-aminoethyl)phosphonic acid Chemical compound [NH3+]CCP(O)([O-])=O QQVDJLLNRSOCEL-UHFFFAOYSA-N 0.000 description 2
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
• RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 2
• YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 102100028282 Bile salt export pump Human genes 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 206010008635 Cholestasis Diseases 0.000 description 2
• 239000004380 Cholic acid Substances 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 208000032928 Dyslipidaemia Diseases 0.000 description 2
• 101150088871 ELOVL6 gene Proteins 0.000 description 2
• 101150003888 FASN gene Proteins 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 208000035150 Hypercholesterolemia Diseases 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102000016267 Leptin Human genes 0.000 description 2
• 108010092277 Leptin Proteins 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 208000017170 Lipid metabolism disease Diseases 0.000 description 2
• SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
• 239000007993 MOPS buffer Substances 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 102100023172 Nuclear receptor subfamily 0 group B member 2 Human genes 0.000 description 2
• 208000012868 Overgrowth Diseases 0.000 description 2
• 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 description 2
• 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
• 241000192142 Proteobacteria Species 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 238000007171 acid catalysis Methods 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
• 150000001336 alkenes Chemical class 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 2
• 208000001088 cerebrotendinous xanthomatosis Diseases 0.000 description 2
• 231100000359 cholestasis Toxicity 0.000 description 2
• 230000007870 cholestasis Effects 0.000 description 2
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
• 235000019416 cholic acid Nutrition 0.000 description 2
• 229960002471 cholic acid Drugs 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 238000005833 cis-dihydroxylation reaction Methods 0.000 description 2
• 239000005516 coenzyme A Substances 0.000 description 2
• 229940093530 coenzyme a Drugs 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 239000008367 deionised water Substances 0.000 description 2
• 229910021641 deionized water Inorganic materials 0.000 description 2
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
• 229960003964 deoxycholic acid Drugs 0.000 description 2
• 150000002009 diols Chemical class 0.000 description 2
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
• 235000019797 dipotassium phosphate Nutrition 0.000 description 2
• 239000003651 drinking water Substances 0.000 description 2
• 235000020188 drinking water Nutrition 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
• 235000013373 food additive Nutrition 0.000 description 2
• 239000002778 food additive Substances 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 238000003304 gavage Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000004153 glucose metabolism Effects 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 238000013224 high-fat diet-induced obese mouse Methods 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 235000003642 hunger Nutrition 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
• 229940039781 leptin Drugs 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 230000006372 lipid accumulation Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
• 238000003305 oral gavage Methods 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• 229910052762 osmium Inorganic materials 0.000 description 2
• SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
• WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 230000001766 physiological effect Effects 0.000 description 2
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 239000002096 quantum dot Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 239000007974 sodium acetate buffer Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 2
• HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
• 229940045145 uridine Drugs 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
• MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
• YARNOIDQQUOOES-VKHMYHEASA-N (2r)-2-amino-2-fluoropropanoic acid Chemical compound C[C@@](N)(F)C(O)=O YARNOIDQQUOOES-VKHMYHEASA-N 0.000 description 1
• MVMQEZPNWYPJIX-VKHMYHEASA-N (2r)-2-amino-2-iodopropanoic acid Chemical compound C[C@@](N)(I)C(O)=O MVMQEZPNWYPJIX-VKHMYHEASA-N 0.000 description 1
• ORQLXCMGAMWKMJ-REOHCLBHSA-N (2r)-2-amino-3-bromopropanoic acid Chemical compound BrC[C@H](N)C(O)=O ORQLXCMGAMWKMJ-REOHCLBHSA-N 0.000 description 1
• DIZAJUVUZKMLQL-REOHCLBHSA-N (2r)-2-amino-3-iodopropanoic acid Chemical compound IC[C@H](N)C(O)=O DIZAJUVUZKMLQL-REOHCLBHSA-N 0.000 description 1
• XCKUCSJNPYTMAE-QMMMGPOBSA-N (2s)-2-(chloroamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](NCl)CC1=CC=CC=C1 XCKUCSJNPYTMAE-QMMMGPOBSA-N 0.000 description 1
• PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 1
• OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
• MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
• MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
• GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 1
• QLOKJRIVRGCVIM-UHFFFAOYSA-N 1-[(4-methylsulfanylphenyl)methyl]piperazine Chemical compound C1=CC(SC)=CC=C1CN1CCNCC1 QLOKJRIVRGCVIM-UHFFFAOYSA-N 0.000 description 1
• 108020004463 18S ribosomal RNA Proteins 0.000 description 1
• UYTSRQMXRROFPU-UHFFFAOYSA-N 2-azaniumyl-3-fluoropropanoate Chemical compound FCC(N)C(O)=O UYTSRQMXRROFPU-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ASBJGPTTYPEMLP-UHFFFAOYSA-N 3-chloroalanine Chemical compound ClCC(N)C(O)=O ASBJGPTTYPEMLP-UHFFFAOYSA-N 0.000 description 1
• MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
• XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
• PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 description 1
• HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
• 231100000582 ATP assay Toxicity 0.000 description 1
• 102100027757 ATP synthase subunit d, mitochondrial Human genes 0.000 description 1
• 206010000060 Abdominal distension Diseases 0.000 description 1
• 241000208140 Acer Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000004672 Acetyl-CoA C-acyltransferase Human genes 0.000 description 1
• 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 1
• 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
• 101710103514 Acyl-coenzyme A oxidase 1 Proteins 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• 102100034083 Alkaline ceramidase 1 Human genes 0.000 description 1
• 101710200052 Alkaline ceramidase 1 Proteins 0.000 description 1
• 102100034082 Alkaline ceramidase 3 Human genes 0.000 description 1
• 101710200049 Alkaline ceramidase 3 Proteins 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 206010004637 Bile duct stone Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 101150041968 CDC13 gene Proteins 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241001466804 Carnivora Species 0.000 description 1
• 102100035401 Ceramide synthase 2 Human genes 0.000 description 1
• 101710146191 Ceramide synthase 2 Proteins 0.000 description 1
• 102100035418 Ceramide synthase 4 Human genes 0.000 description 1
• 101710146190 Ceramide synthase 4 Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
• 201000009331 Choledocholithiasis Diseases 0.000 description 1
• 206010049055 Cholestasis of pregnancy Diseases 0.000 description 1
• 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 1
• 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
• RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010056533 Congenital hepatic fibrosis Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
• 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
• 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 description 1
• 101710114487 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Proteins 0.000 description 1
• 102100022206 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Human genes 0.000 description 1
• 102100027563 Cytochrome c oxidase subunit 5A, mitochondrial Human genes 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 101150027068 DEGS1 gene Proteins 0.000 description 1
• 238000007399 DNA isolation Methods 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 101100170485 Danio rerio sdhdb gene Proteins 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 241000605716 Desulfovibrio Species 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 101150102653 Dgat2 gene Proteins 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 1
• 101710167503 Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 1
• GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
• 102000018642 Elongation of very long chain fatty acids protein 6 Human genes 0.000 description 1
• 108050007786 Elongation of very long chain fatty acids protein 6 Proteins 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 101710153363 Fibroblast growth factor 15 Proteins 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000936976 Homo sapiens ATP synthase subunit d, mitochondrial Proteins 0.000 description 1
• 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
• 101000725076 Homo sapiens Cytochrome c oxidase subunit 5A, mitochondrial Proteins 0.000 description 1
• 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 241001527806 Iti Species 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 102000006835 Lamins Human genes 0.000 description 1
• 108010047294 Lamins Proteins 0.000 description 1
• 101150014058 MMP1 gene Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010025476 Malabsorption Diseases 0.000 description 1
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 241000736262 Microbiota Species 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• VJSBNBBOSZJDKB-KPEYJIHVSA-N N-(15Z)-tetracosenoylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC VJSBNBBOSZJDKB-KPEYJIHVSA-N 0.000 description 1
• CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 1
• CWLQUGTUXBXTLF-YFKPBYRVSA-N N-methylproline Chemical compound CN1CCC[C@H]1C(O)=O CWLQUGTUXBXTLF-YFKPBYRVSA-N 0.000 description 1
• ZBSGKPYXQINNGF-UHFFFAOYSA-N N-nicotinoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CN=C1 ZBSGKPYXQINNGF-UHFFFAOYSA-N 0.000 description 1
• 238000013232 NAFLD rodent model Methods 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 1
• 101710105538 Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010033307 Overweight Diseases 0.000 description 1
• 241000042032 Petrocephalus catostoma Species 0.000 description 1
• 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 description 1
• 101710145828 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Proteins 0.000 description 1
• 102100022771 Phosphatidylcholine:ceramide cholinephosphotransferase 2 Human genes 0.000 description 1
• 101710145833 Phosphatidylcholine:ceramide cholinephosphotransferase 2 Proteins 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 101100187476 Rattus norvegicus Nr1h4 gene Proteins 0.000 description 1
• 108010052090 Renilla Luciferases Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000605947 Roseburia Species 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102000015785 Serine C-Palmitoyltransferase Human genes 0.000 description 1
• 108010024814 Serine C-palmitoyltransferase Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 208000032140 Sleepiness Diseases 0.000 description 1
• 101150094441 Smpd3 gene Proteins 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 102100037416 Sphingolipid delta(4)-desaturase DES1 Human genes 0.000 description 1
• 108700001179 Sphingolipid delta(4)-desaturase DES1 Proteins 0.000 description 1
• 102100021461 Sphingomyelin phosphodiesterase 3 Human genes 0.000 description 1
• 101710201918 Sphingomyelin phosphodiesterase 3 Proteins 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 238000000692 Student's t-test Methods 0.000 description 1
• 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 241001493546 Suina Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 101150033527 TNF gene Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
• 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
• 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
• 108010021119 Trichosanthin Proteins 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 201000010272 acanthosis nigricans Diseases 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229960001445 alitretinoin Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
• 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 239000006286 aqueous extract Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• WPOFMMJJCPZPAO-INIZCTEOSA-N benzyl n-[(2s)-1-hydroxy-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](CO)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 WPOFMMJJCPZPAO-INIZCTEOSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 208000024330 bloating Diseases 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 150000005693 branched-chain amino acids Chemical class 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
• 229960001761 chlorpropamide Drugs 0.000 description 1
• 208000003167 cholangitis Diseases 0.000 description 1
• 230000031154 cholesterol homeostasis Effects 0.000 description 1
• 150000001841 cholesterols Chemical class 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
• RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 108700004333 collagenase 1 Proteins 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000007398 colorimetric assay Methods 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 238000005100 correlation spectroscopy Methods 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 238000002790 cross-validation Methods 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 108010035432 cytochrome C(L) Proteins 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 238000007269 dehydrobromination reaction Methods 0.000 description 1
• KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000004807 desolvation Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000013367 dietary fats Nutrition 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• YEJSPQZHMWGIGP-UHFFFAOYSA-N dl-glutamic acid dimethyl ester Natural products COC(=O)CCC(N)C(=O)OC YEJSPQZHMWGIGP-UHFFFAOYSA-N 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 238000010864 dual luciferase reporter gene assay Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 108010057988 ecdysone receptor Proteins 0.000 description 1
• 230000001729 effect on metabolism Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 101150100705 ehhadh gene Proteins 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
• RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 230000009123 feedback regulation Effects 0.000 description 1
• 231100000502 fertility decrease Toxicity 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 229940044170 formate Drugs 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 208000020694 gallbladder disease Diseases 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960001031 glucose Drugs 0.000 description 1
• 230000014101 glucose homeostasis Effects 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 235000004280 healthy diet Nutrition 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000004730 hepatocarcinogenesis Effects 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 239000011539 homogenization buffer Substances 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229940071870 hydroiodic acid Drugs 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 239000013546 insoluble monolayer Substances 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
• 208000014861 isolated congenital hepatic fibrosis Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229930014550 juvenile hormone Natural products 0.000 description 1
• 239000002949 juvenile hormone Substances 0.000 description 1
• 150000003633 juvenile hormone derivatives Chemical class 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 210000005053 lamin Anatomy 0.000 description 1
• 230000007775 late Effects 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 102000005861 leptin receptors Human genes 0.000 description 1
• 108010019813 leptin receptors Proteins 0.000 description 1
• 230000004132 lipogenesis Effects 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 239000004973 liquid crystal related substance Substances 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 238000012317 liver biopsy Methods 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 150000004668 long chain fatty acids Chemical class 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 108010003814 member 2 group B nuclear receptor subfamily 0 Proteins 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 150000001457 metallic cations Chemical class 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• SEWIYICDCVPBEW-UHFFFAOYSA-N methyl glutamate Chemical compound COC(=O)C(N)CCC(O)=O SEWIYICDCVPBEW-UHFFFAOYSA-N 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 208000008275 microscopic colitis Diseases 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 238000002552 multiple reaction monitoring Methods 0.000 description 1
• WFDHLKUQFQCHKF-UHFFFAOYSA-N n-[[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]-3-fluorobenzamide Chemical group CC(=O)NC1=CC=CC(C=2N=C3N(C=4C=CC(CNC(=O)C=5C=C(F)C=CC=5)=CC=4)C(C=4C(=NC=CC=4)N)=NC3=CC=2)=C1 WFDHLKUQFQCHKF-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 201000009925 nephrosclerosis Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229940127285 new chemical entity Drugs 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 235000021590 normal diet Nutrition 0.000 description 1
• 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 239000012434 nucleophilic reagent Substances 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 229930191479 oligomycin Natural products 0.000 description 1
• MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 108090000629 orphan nuclear receptors Proteins 0.000 description 1
• 102000004164 orphan nuclear receptors Human genes 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229940116315 oxalic acid Drugs 0.000 description 1
• 230000036284 oxygen consumption Effects 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 238000001558 permutation test Methods 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003009 phosphonic acids Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 201000006038 polycystic kidney disease 4 Diseases 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 238000007781 pre-processing Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000000513 principal component analysis Methods 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000001012 protector Effects 0.000 description 1
• 108700022487 rRNA Genes Proteins 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000006894 reductive elimination reaction Methods 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 108090000064 retinoic acid receptors Proteins 0.000 description 1
• 102000003702 retinoic acid receptors Human genes 0.000 description 1
• 150000004492 retinoid derivatives Chemical class 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229940080817 rotenone Drugs 0.000 description 1
• JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 101150114996 sdhd gene Proteins 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 150000004666 short chain fatty acids Chemical class 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 230000037321 sleepiness Effects 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 108010003524 sodium-bile acid cotransporter Proteins 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 238000013179 statistical model Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 102000028561 sterol response element binding proteins Human genes 0.000 description 1
• 108091009326 sterol response element binding proteins Proteins 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000004575 stone Substances 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 239000013595 supernatant sample Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
• 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1